Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Tight liquidity NBB
Cash and receivables cover 59 % of short-term debt in 2025; threshold 65 %.
Financials
Financial year 2025
BLRCE from Lessines, company number BE0734605150, closed financial year 2025 with a result of € -7,484 after tax. For that financial year BLRCE recorded a gross margin of € 236,672 and equity of € 262,951. Compared with financial year 2024, the result moved from € 22,870 to € -7,484. The company made a loss. The company holds a healthy buffer. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on July 9, 2026.
€ 262,951
▼ 37% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -7,484
▼ still € 22,870 profit in 2024
Profit after tax over the fiscal year.
€ 96,430
▼ 50% vs 2024
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € 242,951.
People and assets in 2025
3.2
▲ 0.9 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 131,109
▲ 39% vs 2024
€ 41,000 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 120,683
▲ € 104,262 vs 2024
Of which on lease € 99,060.
Debts at end 2025
€ 943,634
▲ 204% vs 2024
€ 144,163 is repaid this year. At this pace the long-term loan is gone in ≈ 7 years.
€ 208,271
▲ 7% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 25,273
▼ 9% vs 2024
Taxes, VAT and social contributions still to pay.
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 333,356 | € 305,920 | € 258,663 | € 236,672 | ▼ 9% |
| Profit after taxes | € 135,324 | € 121,274 | € 22,870 | € -7,484 | ▼ € 30,354 |
| Equity | € 396,291 | € 397,565 | € 420,435 | € 262,951 | ▼ 37% |
| Total debts | € 579,028 | € 513,327 | € 555,225 | € 1,327,537 | ▲ 139% |
| Cash | € 309,011 | € 218,016 | € 193,804 | € 96,430 | ▼ 50% |
| Land & buildings | € 103,176 | € 117,559 | € 240,186 | € 687,828 | ▲ 186% |
| Retained profit | € 376,291 | € 377,565 | € 400,435 | € 242,951 | ▼ 39% |
| Dividend | € 0 | € 120,000 | € 0 | € 150,000 | |
| Bank debt | € 336,195 | € 264,126 | € 310,243 | € 943,634 | ▲ 204% |
| Balance sheet total | € 975,319 | € 910,893 | € 975,660 | € 1,590,488 | ▲ 63% |
| Employees (FTE) | 2.7 | 2.3 | 2.3 | 3.2 | ▲ 0.9 |
Key figures of BLRCE, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to BLRCE?
What happened at BLRCE in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: loss of € 7,484 (▼ € 30,354 vs 2024). Source: NBB ↗
- New establishment in Lessines. KBO
- Start of the company according to the CBE. KBO
- Laurence BRUNEAU became a director. NBB
In short
From € 135,324 profit in 2022 to € 7,484 loss in 2025.
Paid € 82,618 in corporate taxes since 2022.
Best year ever: 2022, with € 135,324 profit.
On average € 74,000 of value added per employee in 2025.
Management
Behind BLRCE is Laurence BRUNEAU.
Directors
According to the 2025 annual accounts
Laurence BRUNEAU
Director
since 2019
Establishments
Establishment units
Physical locations of this company
Porte d' Ogy(L) 26
7860 Lessines
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0734.605.150
- VAT number
- BE 0734.605.150
- Registered office
- Porte d' Ogy(L) 26, 7860 Lessines
- Names & denominations
- BLRCE · Pharmacie de la Porte d'Ogy
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 18 September 2019
- Peppol
- Active · Active since 10 Dec 2025
- Activities · NACE
Detailhandel in farmaceutische producten
Vervaardiging van overige farmaceutische producten